The rational design of molecular glues has historically proved challenging, however, we anticipate breakthroughs in this space in 2024,” he said.
Neil Torbett, CEO of PhoreMost believes 2024 will be transformative for the TPD space. Following a substantial increase in disclosed bivalent degrader drugs and clinical trials in 2023, he expects to see increased interest from investors and pharma this year as advanced Proteolysis Targeting Chimeras (PROTACs) enter phase 3 clinical trials. “ Molecular glues are an exciting new approach to degrader therapeutics, offering improved pharmacological properties in new therapeutic areas. The rational design of molecular glues has historically proved challenging, however, we anticipate breakthroughs in this space in 2024,” he said.